Your browser doesn't support javascript.
loading
Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.
Kumagai, Takashi; Nakaseko, Chiaki; Nishiwaki, Kaichi; Yoshida, Chikashi; Ohashi, Kazuteru; Takezako, Naoki; Takano, Hina; Kouzai, Yasuji; Murase, Tadashi; Matsue, Kosei; Morita, Satoshi; Sakamoto, Junichi; Wakita, Hisashi; Sakamaki, Hisashi; Inokuchi, Koiti.
Afiliação
  • Kumagai T; Department of Hematology, Ome Municipal General Hospital, Tokyo, Japan.
  • Nakaseko C; Department of Hematology, Chiba University Hospital, Chiba, Japan.
  • Nishiwaki K; Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Kashiwa Hospital, Chiba, Japan.
  • Yoshida C; Department of Hematology, National Hospital Organization, Mito Medical Center, Higashiibarakigun, Japan.
  • Ohashi K; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Takezako N; Department of Hematology, National Hospital Organization Disaster Medical Center, Tachikawa, Japan.
  • Takano H; Department of Hematology, Musashino Red Cross Hospital, Musashino, Japan.
  • Kouzai Y; Department of Hematology, Tokyo Metropolitan Tama Synthesis Medical Center, Tokyo, Japan.
  • Murase T; Department of Laboratory Medicine, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
  • Matsue K; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Morita S; Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Sakamoto J; Tokai Central Hospital, Kakamigahara, Japan.
  • Wakita H; Division of Hematology and Oncology, Japanese Red Cross Society, Narita Red Cross Hospital, Narita, Japan.
  • Sakamaki H; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Inokuchi K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Cancer Sci ; 109(1): 182-192, 2018 Jan.
Article em En | MEDLINE | ID: mdl-29058817
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Dasatinibe / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Sci Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Dasatinibe / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Sci Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão